Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

TG Therapeutics Inc. (TGTX)

NASDAQ: TGTX · Pharmaceutical Preparations · New York, NY

Our rating: Neutral

Neutral reaffirmed at $64.26, moderate conviction, November 10, 2026.

Breaks if: The Neutral call turns Positive if TG Therapeutics reports free cash flow above $150M in either of the next two quarterly filings, confirming that net income is converting to real cash and resolving the earnings-quality overhang. It turns Cautious if revenue growth decelerates to below 25% year-over-year in either of the next two quarterly reports, signaling that BRIUMVI's commercial ramp is flattening before the valuation has been grown into.

Key figures

Market value$9.6B
Revenue, last 12 months$898M
Net income, last 12 months$106M
Free cash flow, last 12 months$86M
Price to earnings90.3×
Free cash flow yield0.9%
Dividend yield0.0%
Operating margin21.5%
Return on equity18.0%
Beta to the S&P 5000.77
Volatility, annualized53.4%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$260M60.7%$0.35$45M
June 30, 2026$240M70.3%$0.05$39M
March 31, 2026$205M69.6%$0.12−$18M
December 31, 2025$193M78.0%$0.15$20M
September 30, 2025$162M92.8%$2.43−$23M
June 30, 2025$141M92.1%$0.17$7M
March 31, 2025$121M90.4%$0.03−$29M
December 31, 2024$108M146.0%$0.15−$26M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

14 ledger entries and 87 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.